-- ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer -- Estimated OS at 12...
RESEARCH TRIANGLE PARK, N.C., July 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...
Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2...
VANCOUVER, BC / ACCESSWIRE / July 2, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") announces that pursuant...